Omacetaxine mepesuccinate is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Omacetaxine mepesuccinate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Omacetaxine mepesuccinate overview
Omacetaxine mepesuccinate (Homoharringtonine, Omapro, Synribo, Tekinex, CGX635) is an antineoplastic agent. It is formulated as injection, administered by subcutaneous route. It is indicated for the treatment of chronic myelocytic Leukemia.
The drug candidate is also under development for the treatment of myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. It was also under development for the treatment of Philadelphia chromosome-positive (Ph+), acute promyelocytic leukemia (APL), acute myelocytic leukemia (AML), solid tumors including breast cancer, lung cancer, head and neck cancer, colorectal cancer, melanoma and sarcoma.
Teva Pharmaceutical Industries overview
Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in various dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It also focuses on developing generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and international markets. Teva is headquartered in Tel Aviv, Israel.
For a complete picture of Omacetaxine mepesuccinate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
